DOP017: Colectomy Free Survival is Independent of Initial Infliximab Dosing Strategy in Hospitalised Ulcerative Colitis PatientsECCO'16 DOP 2016
1
DOP019: Efficacy of Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's DiseaseECCO'16 DOP 2016
1
DOP022: Targeting Immune Cell Metabolism: LYC-30937, A Novel Therapeutic Approach for Inflammatory Bowel DiseaseECCO'16 DOP 2016
1
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseasesECCO'16 DOP 2016
1
DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitisECCO'16 DOP 2016
1
DOP027: Large scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapyECCO'16 DOP 2016
1
DOP028: Efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohortECCO'16 DOP 2016
1
DOP029: Outcomes of a managed switching program changing IBD patients established on originator infliximab to biosimilar infliximabECCO'16 DOP 2016
1
DOP030: Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort studyECCO'16 DOP 2016
1
DOP031: Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis – data from two Central European countriesECCO'16 DOP 2016
1
DOP032: 28Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safeECCO'16 DOP 2016
1
DOP034: Comparative effectiveness of infliximab and adalimumab in Crohn’s disease: results from a real-life population-based cohortECCO'16 DOP 2016
1